107 related articles for article (PubMed ID: 36325701)
1. VALIDATION OF A PANEL OF BIOMARKERS ASSOCIATED WITH AGGRESSIVE PHENOTYPE OF ENDOMETRIOID CARCINOMA OF ENDOMETRIUM.
Buchynska LG; Iurchenko NP; Nesina IP; Glushchenko NM
Exp Oncol; 2022 Nov; 44(3):234-238. PubMed ID: 36325701
[TBL] [Abstract][Full Text] [Related]
2. Molecular phenotype of high-grade endometrioid carcinoma of the endometrium.
Buchynska LG; Glushchenko NM; Nesina IP; Brieieva OV; Iurchenko NP
Exp Oncol; 2020 Dec; 42(4):300-305. PubMed ID: 33355863
[TBL] [Abstract][Full Text] [Related]
3. Assessment of HER-2/neu, с-MYC and CCNE1 gene copy number variations and protein expression in endometrial carcinomas.
Buchynska LG; Brieieva OV; Iurchenko NP
Exp Oncol; 2019 Jun; 41(2):138-143. PubMed ID: 31262163
[TBL] [Abstract][Full Text] [Related]
4. Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade.
Soovares P; Pasanen A; Similä-Maarala J; Bützow R; Lassus H
Gynecol Oncol; 2022 Jan; 164(1):187-194. PubMed ID: 34711431
[TBL] [Abstract][Full Text] [Related]
5. Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers.
Ramalingam P; Masand RP; Euscher ED; Malpica A
Int J Gynecol Pathol; 2016 Sep; 35(5):410-8. PubMed ID: 26598976
[TBL] [Abstract][Full Text] [Related]
6. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
Fadare O; Parkash V
Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
[TBL] [Abstract][Full Text] [Related]
7. Endometrioid Endometrial Carcinoma With Spindle Cells-Aberrant p16 and p53 Expression.
Sonawane S; Elfituri O; Zhang Y; Yordan E; Ree N
Int J Surg Pathol; 2019 Apr; 27(2):203-207. PubMed ID: 29953305
[TBL] [Abstract][Full Text] [Related]
8. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
Halperin R; Zehavi S; Habler L; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2001; 22(2):122-6. PubMed ID: 11446475
[TBL] [Abstract][Full Text] [Related]
9. СD44+/CD24- markers of cancer stem cells in patients with breast cancer of different molecular subtypes.
Chekhun SV; Zadvorny TV; Tymovska YO; Anikusko MF; Novak OE; Polishchuk LZ
Exp Oncol; 2015 Mar; 37(1):58-63. PubMed ID: 25804234
[TBL] [Abstract][Full Text] [Related]
10. ROLE OF STROMAL MICROENVIRONMENT IN THE FORMATION OF INVASIVE, ANGIOGENIC, AND METASTATIC POTENTIAL OF ENDOMETRIOID CARCINOMA OF ENDOMETRIUM.
Iurchenko NP; Nesina IP; Glushchenko NМ; Buchynska LG
Exp Oncol; 2023 Jun; 45(1):51-61. PubMed ID: 37417282
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade.
Urabe R; Hachisuga T; Kurita T; Kagami S; Kawagoe T; Matsuura Y; Shimajiri S
J Obstet Gynaecol Res; 2014 Mar; 40(3):812-9. PubMed ID: 24246002
[TBL] [Abstract][Full Text] [Related]
12. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
13. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
[TBL] [Abstract][Full Text] [Related]
14. Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma.
Arai T; Watanabe J; Kawaguchi M; Kamata Y; Nishimura Y; Jobo T; Kuramoto H
Int J Gynecol Cancer; 2006; 16(1):391-5. PubMed ID: 16445664
[TBL] [Abstract][Full Text] [Related]
15. Computerized image analysis of p53 and proliferating cell nuclear antigen expression in benign, hyperplastic, and malignant endometrium.
Elhafey AS; Papadimitriou JC; El-Hakim MS; El-Said AI; Ghannam BB; Silverberg SG
Arch Pathol Lab Med; 2001 Jul; 125(7):872-9. PubMed ID: 11419970
[TBL] [Abstract][Full Text] [Related]
16. Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis?
Gülseren V; Kocaer M; Özdemir İA; Çakır İ; Sancı M; Güngördük K
Curr Probl Cancer; 2020 Feb; 44(1):100498. PubMed ID: 31395281
[TBL] [Abstract][Full Text] [Related]
17. Postoperative autovaccinotherapy for patients with gastric cancer and expression of some proteins in tumor tissue.
Bazas VM; Lukyanova NY; Lisovenko GS; Rozumiy DO; Potebnya GP
Exp Oncol; 2009 Sep; 31(3):182-4. PubMed ID: 19783961
[TBL] [Abstract][Full Text] [Related]
18. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma.
Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S
Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241
[TBL] [Abstract][Full Text] [Related]
19. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
20. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
